{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:19:35Z","timestamp":1778314775576,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.pnpbp.2013.01.008","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T21:16:31Z","timestamp":1358543791000},"page":"29-33","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients"],"prefix":"10.1016","volume":"44","author":[{"given":"Aitor","family":"Palomino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Martinez-Cengotitabengoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Ruiz de Azua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Alberich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Matute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2013.01.008_bb0005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.pneurobio.2009.07.008","article-title":"Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan","volume":"89","author":"Aleman","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0010","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.biopsych.2008.08.031","article-title":"Insulin, IGF-1, and muscarinic agonists modulate schizophrenia-associated genes in human neuroblastoma cells","volume":"64","author":"Altar","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0015","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/08977190701602329","article-title":"Running exercise- and antidepressant-induced increases in growth and survival-associated signaling molecules are IGF-dependent","volume":"25","author":"Chen","year":"2007","journal-title":"Growth Factors"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0020","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bbr.2008.11.016","article-title":"Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise","volume":"198","author":"Duman","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0025","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0030","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1002\/jnr.22484","article-title":"Dystroglycan modulates the ability of insulin-like growth factor-1 to promote oligodendrocyte differentiation","volume":"88","author":"Galvin","year":"2010","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0303-7207(98)00035-5","article-title":"Asphyxial brain injury\u2014the role of the IGF system","volume":"140","author":"Gluckman","year":"1998","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1192\/bjp.185.4.353-a","article-title":"Insulin-like growth factors, insulin resistance and schizophrenia","volume":"185","author":"Gunnell","year":"2004","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1464-5491.2003.00827.x","article-title":"The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis","volume":"20","author":"Holt","year":"2003","journal-title":"Diabet Med"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature09552","article-title":"Rethinking schizophrenia","volume":"468","author":"Insel","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.mehy.2011.06.001","article-title":"Recombinant human IGF-1 for patients with schizophrenia","volume":"77","author":"Khalil","year":"2011","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1155\/EDR.2003.205","article-title":"The insulin-like growth factor system","volume":"4","author":"Le","year":"2003","journal-title":"Exp Diabesity Res"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0075","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuropharm.2006.07.006","article-title":"Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats","volume":"51","author":"Lin","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0080","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4088\/JCP.v60n1112","article-title":"Different influences of classical antipsychotics and clozapine on glucose\u2013insulin homeostasis in patients with schizophrenia or related psychoses","volume":"60","author":"Melkersson","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2125.2001.01352.x","article-title":"Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses","volume":"51","author":"Melkersson","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0090","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1523\/JNEUROSCI.20-11-04165.2000","article-title":"Insulin-like growth factor I stimulates dendritic growth in primary somatosensory cortex","volume":"20","author":"Niblock","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0095","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1192\/bjp.bp.106.034694","article-title":"Growth trajectory during early life and risk of adult schizophrenia","volume":"191","author":"Perrin","year":"2007","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0024-3205(02)01646-6","article-title":"Physical consequences of schizophrenia and its treatment: the metabolic syndrome","volume":"71","author":"Ryan","year":"2002","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","article-title":"Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia","volume":"160","author":"Ryan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0b013e3181e62076","article-title":"High insulin like growth factor I is associated with cognitive decline in Huntington disease","volume":"75","author":"Saleh","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0115","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1176\/appi.ajp.2007.07020233","article-title":"Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia","volume":"164","author":"Venkatasubramanian","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2010.01.033","article-title":"Effect of antipsychotic treatment on insulin-like growth factor-1 and cortisol in schizophrenia: a longitudinal study","volume":"119","author":"Venkatasubramanian","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0125","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1034\/j.1600-0447.2001.00280.x","article-title":"Associations between childhood living circumstances and schizophrenia: a population-based cohort study","volume":"104","author":"Walhbeck","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2013.01.008_bb0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T13:53:55Z","timestamp":1562594035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584613000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":26,"alternative-id":["S0278584613000109"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.01.008","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}